Overview

* Curaleaf ( CURLF ) Q3 revenue of $320 mln slightly beats analyst expectations

* Company's international revenue grows 56% yr/yr, driving overall growth

* Adjusted gross margin improves to 50%, up 115 basis points yr/yr

Outlook

* Curaleaf ( CURLF ) sees positive momentum despite macroeconomic pressures

* Company aims to enhance product quality and expand margins

* Curaleaf ( CURLF ) plans to leverage Dark Heart genetics for renewed growth

Result Drivers

* INTERNATIONAL GROWTH - International revenue grew 56% yr/yr, significantly contributing to overall growth

* DOMESTIC STABILITY - Domestic segment remained stable with modest growth despite price compression challenges

* STRATEGIC INITIATIVES - Return to Our Roots plan enhances product quality and expands margins

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight $320 mln $316.82

Revenue Beat* mln (8

Analysts

)

Q3 $69 mln

Adjusted

EBITDA

Q3 Gross $159.70

Profit mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Curaleaf Holdings Inc ( CURLF ) is C$4.13, about 8.8% above its November 4 closing price of C$3.76

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)